Is there a role for PD-1 inhibitors for metastatic or locally recurrent cutaneous squamous cell carcinomas after failure of first line therapy, EGFR inhibitors?   

Is it commonly used if no clinical trials are available?



Answer from: Medical Oncologist at Academic Institution